التداخل بين إيفاكافتور وبريميدون

Concomitant Use with CYP3A Inducers Use of KALYDECO with strong CYP3A inducers, such as rifampin, substantially decreases the exposure of ivacaftor, which may reduce the therapeutic effectiveness of KALYDECO.

Inducers of CYP3A Co-administration with rifampin, a strong CYP3A inducer, significantly decreased ivacaftor exposure (AUC) by approximately 9-fold.

Use with CYP3A inducers: Concomitant use with strong CYP3A inducers (e.g., rifampin, St.

Therefore, co-administration of KALYDECO with strong CYP3A inducers (e.g., rifampin, St.

Therefore, co-administration with strong CYP3A inducers, such as rifampin, rifabutin, phenobarbital, carbamazepine, phenytoin, and St.